Ocular side‐effects of tolterodine and oxybutynin, a single‐blind prospective randomized trial

Abstract

Four weeks of standard-dose oxybutynin treatment in women with overactive bladder decreases AA significantly, whereas the same duration of standard-dose tolterodine does not have this effect. However, tolterodine seemed to affect PD in dim light. One month of treatment with either of these anticholinergic drugs shortens tear film break-up time significantly. Concerning ocular side-effects, tolterodine seems to offer an advantage over oxybutynin because it does not affect AA, however, the shorter tear film break-up time with both agents suggests potential problems for patients who already have dry eye.

Comparision effects of solifenacin, darifenacin, propiverine on ocular parameters in eyes: A prospective study

“…The authors then compared the patient's IOPs and PDs with the initial values at the four-week follow-up. No significant difference was found among the initial values except for PD in dark light in the group that used tolterodine (3.72 vs. 4.16mm, p=0.025) (29). In this study, neither agent affected tear secretion.…”

Oxybutynin-associated esotropia

“…2 In our 5-yearold girl, similar reduction in accommodative amplitude in combination with her uncorrected moderate hypermetropia may have driven the need to generate accommodation using other available physiological mechanisms such as convergence accommodation/convergence ratio. The result was esotropia secondary to inappropriate convergence in excess of her fusional reserves.…”

“…Systemic side effects can be expected. 1 Ocular side effects such as dry eyes, burning or foreign body sensation, and reduced accommodation 2 have been described in adults. We believe that esotropia has not been previously been described in association with the use of oxybutynin in either the adult or the pediatric population.…”

Urologic medications and ophthalmologic side effects: a review

“…In a small single-blind prospective randomized trial, there was no change in intraocular pressure from baseline in patients taking either 2 mg of tolterodine twice a day or 5 mg oxybutynin three times a day. 54 A group from Japan outlined their practices in a review of 367 patients initiated on anticholinergics for OAB. All patients were asked about a glaucoma history and, if positive, were referred to an ophthalmologist to clarify the type of glaucoma.…”